ARTICLE | Company News
Dilaforette, Ergomed deal
March 2, 2015 8:00 AM UTC
Dilaforette will pay Ergomed an undisclosed sum to conduct an international Phase II trial of Dilaforette’s sevuparin to treat vaso-occlusive crisis (VOC) in patients with sickle cell disease. Ergomed...